Visoluten®
in comparison with the indicators before treatment and with indicators in the control group and
approaching the physiological norm. The indicators in the control group, whose patients received
conventional treatment, significantly differ from the before treatment but do not reach the boundaries
of the physiological norm.
The use of VISOLUTEN® in post-traumatic keratoconjunctivitis had a stimulating effect on the
cornea’s reparative regeneration, promoting the formation of more delicate corneal scars, increasing
the effectiveness of the treatment by 1.4 times and providing a more stable therapeutic effect in
comparison with the results in the control group. The phenomena of blepharospasm, photophobia, and
lacrimation in patients receiving VISOLUTEN® disappeared 2.4 times faster than in the control group.
The effect of VISOLUTEN® on electroretinography indicators in Table 3
patients with degenerative diseases of the retina
Indicators Norm Before Treatment After Treatment with After Treatment with
Conventional Methods Visoluten®
Wave «А» μV 30-60 18,6±1,0 24,6±1,6* 33,2±1,5*#
mS 15-25 19,7±1,3 22,5±2,7 23,1±1,9
Wave «В» μV 225-400 119,7±8,9 178,3±9,4* 216,3±10,3*#
mS 37-50 57,5±1,9 51,6±1,3 53,2±2,1
* p <0.05 - statistically significant in comparison with the indicator before treatment;
# p <0.05 - statistically significant in comparison with the indicator in the control group.
The appointment of VISOLUTEN® in the postoperative period after keratoplasty and vitreoretinal
operations made it possible in 86.7% of cases to prevent postoperative complications and shorten
the rehabilitation period.
VISOLUTEN® does not cause side effects, complications, or drug dependence.
The obtained results from the clinical study of the drug indicate the therapeutic efficacy of VISOLUTEN®
and the practicality of its use in the complex treatment of patients with dystrophic diseases of the retina
and post-traumatic epithelial-endothelial corneal dystrophies, keratoconjunctivitis, as well as in the
postoperative period in combination with symptomatic and pathogenetic drugs as an additional agent.
CONCLUSION
Biologically active food supplement VISOLUTEN®has a normalizing effect on the metabolism of the
eyeball tissues and helps restore the optical structures of the eye.
VISOLUTEN® is well tolerated when taken orally, has no side effects, and can be widely used as a
therapeutic and prophylactic biologically active food supplement.
VISOLUTEN® is recommended for use:
- To patients with degenerative diseases of the retina - orally 10-15 minutes before meals, 1-3 capsules
2-3 times a day for 15-30 days, depending on the severity of the pathological process;
- To patients with post-traumatic corneal dystrophies - orally 10-15 minutes before meals, 2-3 capsules
2-3 times a day for 15-30 days, depending on the severity of the pathological process;
- For prophylactic purposes in people whose professional activity is associated with eye strain, work in
dusty and smoky rooms - orally 10-15 minutes before meals, 1 capsule 2 times a day for 15-30 days.
According to indications, a second course of treatment is recommended after 3-6 months.
It is advisable to recommend VISOLUTEN® for therapeutic and prophylactic use and industrial
production.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.